Pharmaceuticals, Biotechnology and Life Sciences
U.S. District Court rules Dana-Farber scientist Gordon Freeman, PhD,was co-inventor of all six patents in issue
– Ongoing Phase 2 ACCURACY study to explore AL101 and its effect on tumor growth inhibition in people with Adenoid…
The global pulmonary embolism therapeutics market is expected to post aCAGR of more than 9% during the period 2019-2023, according to thelatest market research report by Technavio.
DUBLIN–(BUSINESS WIRE)–The “Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027” report has been added to ResearchAndMarkets.com’s offering. The…
ImaginAb has enrolled its first patient for the Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at City of Hope in Los Angeles County.
Boehringer Ingelheim’s the trial did not meet its primary endpoint, which was to show aclinically significant difference between dabigatran etexilate and ASAon reducing the risk of a recurrent stroke among post-stroke patientswith ESUS.
Roche study showed entrectinib shrank tumours (objective response rate; ORR) in all children and adolescents who had NTRK, ROS1 or ALK fusion-positive solid tumours (11 of 11 patients), including two patients achieving a complete response.
Revenues increased approximately 19.5% to €35.2 million, compared with €29.5 million during the same period last year.
4D pharma’s study of Thetanix for treating Crohn’s disease has met primary objective, as it showed Thetanix was well tolerated with a good safety profile.
Contained and sterile transfer solutions expert, ChargePoint Technology, has appointed Stephen Eastick as UK Sales Manager.